Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis.
Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzàlez-Juncà A, Sodir NM, Massó-Vallés D, Beaulieu ME, Swigart LB, Mc Gee MM, Somma MP, Nasi S, Seoane J, Evan GI, Soucek L. Annibali D, et al. Among authors: beaulieu me. Nat Commun. 2014 Aug 18;5:4632. doi: 10.1038/ncomms5632. Nat Commun. 2014. PMID: 25130259 Free PMC article.
Strategies to Inhibit Myc and Their Clinical Applicability.
Whitfield JR, Beaulieu ME, Soucek L. Whitfield JR, et al. Among authors: beaulieu me. Front Cell Dev Biol. 2017 Feb 23;5:10. doi: 10.3389/fcell.2017.00010. eCollection 2017. Front Cell Dev Biol. 2017. PMID: 28280720 Free PMC article. Review.
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC.
Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L. Jauset T, et al. Among authors: beaulieu me. Oncotarget. 2018 Apr 10;9(27):18734-18746. doi: 10.18632/oncotarget.24648. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721157 Free PMC article.
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.
Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sánchez-Hervás M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MÁ, Whitfield JR, Lavigne P, Soucek L. Beaulieu ME, et al. Sci Transl Med. 2019 Mar 20;11(484):eaar5012. doi: 10.1126/scitranslmed.aar5012. Sci Transl Med. 2019. PMID: 30894502 Free PMC article.
Finding MYCure.
Beaulieu ME, Soucek L. Beaulieu ME, et al. Mol Cell Oncol. 2019 Jun 20;6(5):e1618178. doi: 10.1080/23723556.2019.1618178. eCollection 2019. Mol Cell Oncol. 2019. PMID: 31528695 Free PMC article.
Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies.
Pesarrodona M, Jauset T, Díaz-Riascos ZV, Sánchez-Chardi A, Beaulieu ME, Seras-Franzoso J, Sánchez-García L, Baltà-Foix R, Mancilla S, Fernández Y, Rinas U, Schwartz S Jr, Soucek L, Villaverde A, Abasolo I, Vázquez E. Pesarrodona M, et al. Among authors: beaulieu me. Adv Sci (Weinh). 2019 Jul 24;6(18):1900849. doi: 10.1002/advs.201900849. eCollection 2019 Sep 18. Adv Sci (Weinh). 2019. PMID: 31559131 Free PMC article.
MYC, MYCL, and MYCN as therapeutic targets in lung cancer.
Massó-Vallés D, Beaulieu ME, Soucek L. Massó-Vallés D, et al. Among authors: beaulieu me. Expert Opin Ther Targets. 2020 Feb;24(2):101-114. doi: 10.1080/14728222.2020.1723548. Epub 2020 Feb 13. Expert Opin Ther Targets. 2020. PMID: 32003251 Review.
34 results